From Nasdaq: 2025-04-15 22:23:00

Telix Pharmaceuticals Limited reports positive preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma, showing a median overall survival of 12.4 months. The treatment was well tolerated with no serious adverse events reported. Telix continues to investigate TLX101 in front-line and recurrent settings, with plans for a registration-enabling study in recurrent glioblastoma. The company aims to commence patient enrollment at Australian sites in the second half of 2025 and submit an IND application in the first half of 2025 for U.S. sites. IPAX-2, a Phase 1/2 study in front-line glioblastoma, is ongoing.



Read more at Nasdaq: Telix Announces Promising Preliminary Results From Phase 2 TLX101 Brain Cancer Study